Significant impact of mTORC1 and ATF4 pathways in CHO cell recombinant protein production induced by CDK4/6 inhibitor.
Sign Up to like & getrecommendations! Published in 2022 at "Biotechnology and bioengineering"
DOI: 10.1002/bit.28050
Abstract: The CDK4/6 inhibitor has been shown to increase recombinant protein productivity in Chinese hamster ovary cells (CHO). Therefore, we investigated the mechanism that couples cell cycle inhibitor (CCI) treatment with protein productivity utilizing proteomics and… read more here.
Keywords: recombinant protein; phosphorylation; mtorc1; cdk4 inhibitor ... See more keywords
CDK4/6 inhibitor protects chemerin‐induced human granulosa‐lutein cells from apoptosis by inhibiting the p53/p21 waf pathway
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Reproduction and Development"
DOI: 10.1002/mrd.23241
Abstract: Dysregulation of the cell cycle is common in human tumorigenesis. Therefore, CDK4/6 inhibitors targeting the cell cycle have been developed, and their antiapoptotic effects have been highly correlated with potential clinical therapies. The aim of… read more here.
Keywords: cdk4 inhibitor; hgl cells; chemerin induced; granulosa lutein ... See more keywords
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Sign Up to like & getrecommendations! Published in 2020 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-00917-8
Abstract: Purpose of Review Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment landscape for patients with hormone receptor-positive (HR+) and HER2-negative (HER2−) metastatic breast cancer (MBC). However, optimal therapy after CDK4/6 inhibitors is… read more here.
Keywords: cdk4 inhibitor; cdk4; breast cancer; cdk4 inhibitors ... See more keywords
CDK4/6 inhibitor protects against myocardial cells apoptosis by inhibiting RB phosphorylation in H9c2 cells.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.01.015
Abstract: Cell cycle dysregulation is typical in human cancers, and CDK4/6 inhibitors targeting cell cycle have potential antiapoptosis effect. The aim of this work is to identify the regulatory effect of Palbociclib on apoptosis of H9c2… read more here.
Keywords: cdk4 inhibitor; h9c2 cells; protects myocardial; h9c2 ... See more keywords
Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
Sign Up to like & getrecommendations! Published in 2022 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2022/2402567
Abstract: Objective To study the expression and prognostic value of CDK6 in stomach cancer and the function of CDK4/6 inhibitor PD-0332991 on the proliferation of stomach cancer cells. Methods Immunohistochemistry was used to detect the expression… read more here.
Keywords: cdk4 inhibitor; cancer; inhibitor 0332991; cancer cells ... See more keywords
Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1522
Abstract: The recent FDA approvals of palbociclib, ribociclib, and abemaciclib in breast cancer validate cyclin-dependent kinases 4 and 6 (CDK4/6) as key therapeutic targets, and warrant investigations in other tumor types with frequently observed alterations in… read more here.
Keywords: cdk4 inhibitor; models non; response; cancer ... See more keywords
Abstract 5975: Discovery of mechanisms that modulate the hippo pathway and CDK6 expression in CDK4/6 inhibitor resistant breast cancer cells
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5975
Abstract: Hormone positive (HR+) breast cancer is the most common subtype in this population. The current standard of care in advanced HR+ breast cancer includes endocrine therapy (tamoxifen, aromatase inhibitors, etc) and CDK4/6 inhibitors. CDK4/6 inhibitors… read more here.
Keywords: cdk4 inhibitor; breast cancer; cdk4; cancer ... See more keywords
Abstract 5991: Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5991
Abstract: CDK4/6 inhibitors give clinical benefit in the treatment of metastatic ER+/HER2- breast cancer (mBC) in combination with endocrine therapy. Although this class of inhibitor has been extensively studied in several other cancer types, CDK4/6 inhibitors… read more here.
Keywords: cdk4 inhibitor; development; cdk4; treatment ... See more keywords
Abstract PS19-10: Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ps19-10
Abstract: Background: The cyclin-dependent kinase (CDK) 4/6 inhibitors ribociclib, abemaciclib, and palbociclib have been established as effective treatment options for hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) breast cancer. While these agents have… read more here.
Keywords: cdk4 cdk6; cdk4 inhibitor; cancer; head ... See more keywords
CDK4/6 inhibitor and radiation therapy in malignant pleural mesothelioma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e24326
Abstract: e24326Background: The prognosis of malignant pleural mesothelioma (MPM) is very poor; a new drug for MPM is need. The percentage of p16 loss in MPM patients is high. We hypothesized that CDK4/6 is ... read more here.
Keywords: cdk4 inhibitor; radiation therapy; inhibitor radiation; pleural mesothelioma ... See more keywords
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.1016
Abstract: 1016 Background: The combination of CDK4/6 inhibitor (CDK4/6i) + endocrine therapy (ET) provides consistent improvement in PFS and response rates compared with single-agent ET as first- or subsequent-line therapy in HR+, HER2− advanced breast cancer… read more here.
Keywords: therapy; cdk4 inhibitor; triplet therapy; her2 advanced ... See more keywords